NCT06545942 2026-04-17
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Active not recruiting
MOMA Therapeutics
The Methodist Hospital Research Institute
Institut National de la Santé Et de la Recherche Médicale, France
National Cancer Institute (NCI)
Artios Pharma Ltd
National Cancer Institute (NCI)